Shots:

• The sBLA is based on P-II KEYNOTE-017 study including ORR and DOR for 1L merkel cell carcinoma(MCC)- study shows most DTC in MCC patients
• The US has set a PDUFA date of Dec 28- 2018- additionally Keytruda also received a BT Designation by FDA in July 2017
• Keytruda (pembrolizumab) 100mg IV is being evaluated in >800 ongoing trials across different tumours in various geographies

 Ref: Merck & Co. | Image: Merck